Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2003

01-02-2003 | Review

Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer

Authors: Angel Alkarain, Joyce Slingerland

Published in: Breast Cancer Research | Issue 1/2003

Login to get access

Abstract

p27 is a key regulator of progression from G1 to S phase. Although the gene encoding p27 is rarely mutated in human cancers, p27 is functionally inactivated in a majority of human cancers through accelerated p27 proteolysis, through sequestration by cyclin D–cyclin-dependent kinase complexes and by cytoplasmic mislocalization. Here we review mechanisms whereby oncogenic activation of receptor tyrosine kinase and Ras pathways lead to accelerated p27 proteolysis and p27 mislocalization in cancer cells. The prognostic significance of p27 in human breast cancer is also reviewed.
Literature
1.
2.
Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995, 9: 1149-1163.PubMedCrossRef
3.
Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J: G1 control in mammalian cells. J Cell Sci Suppl. 1994, 18: 69-73.PubMedCrossRef
4.
Murray AW: Creative blocks: cell cycle checkpoints and feedback controls. Nature. 1992, 359: 599-604.PubMedCrossRef
5.
Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 1992, 71: 543-546.PubMedCrossRef
6.
7.
Slingerland J, Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000, 183: 10-17.PubMedCrossRef
8.
Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13: 1501-1512.PubMedCrossRef
9.
LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997, 11: 847-862.PubMedCrossRef
10.
Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ: The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999, 18: 1571-1583.PubMedPubMedCentralCrossRef
11.
Koff A, Ohtsuki M, Polyak K, Roberts JM, Massagué J: Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science. 1993, 260: 536-539.PubMedCrossRef
12.
Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI: A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA. 1994, 91: 5291-5295.PubMedPubMedCentralCrossRef
13.
Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massagué J, Roberts JM, Koff A: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 1994, 8: 9-22.PubMedCrossRef
14.
Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol. 1994, 14: 3683-3694.PubMedPubMedCentralCrossRef
15.
Ciarallo S, Subramaniam V, Hung W, Lee JH, Kotchetkov R, Sandhu C, Milic A, Slingerland JM: Altered p27Kip1 phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor β-mediated G1 arrest. Mol Cell Biol. 2002, 22: 2993-3002.PubMedPubMedCentralCrossRef
16.
Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science. 1996, 271: 1861-1864.PubMedCrossRef
17.
Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, Koff A: Enhanced ribosomal association of p27Kip1 mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem. 1997, 272: 7093-7098.PubMedCrossRef
18.
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin–proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995, 269: 682-685.PubMedCrossRef
19.
Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakidis TR, Roberts JM: A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature. 2001, 413: 323-327.PubMedCrossRef
20.
Kwon TK, Nagel JE, Buchholz MA, Nordin AA: Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. Gene. 1996, 180: 113-120.PubMedCrossRef
21.
Menjo M, Kaneko Y, Ogata E, Ikeda K, Nakanishi M: Critical role for p27Kip1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3). Oncogene. 1998, 17: 2619-2627.PubMedCrossRef
22.
Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massagué J, Scher HI: Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst. 1998, 90: 1284-1291.PubMedCrossRef
23.
Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, Hirano T, Horn F, Behrmann I: Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/ Kip1. Oncogene. 1999, 18: 3742-3753.PubMedCrossRef
24.
Medema RH, Kops GJ, Bos JL, Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 2000, 404: 782-787.PubMedCrossRef
25.
Connor MK, Kotchetkov R, Cariou S, Resch A, Lupetti R, Beniston RG, Melchior F, Hengst L, Slingerland JM: CRM1/Ran-mediated nuclear export of p27Kip1 involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell. 2003, 14: 201-213.PubMedPubMedCentralCrossRef
26.
Zeng Y, Hirano K, Hirano M, Nishimura J, Kanaide H: Minimal requirements for the nuclear localization of p27Kip1, a cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun. 2000, 274: 37-42.PubMedCrossRef
27.
Guan T, Kehlenbach RH, Schirmer EC, Kehlenbach A, Fan F, Clurman BE, Arnheim N, Gerace L: Nup50, a nucleoplasmically oriented nucleoporin with a role in nuclear protein export. Mol Cell Biol. 2000, 20: 5619-5630.PubMedPubMedCentralCrossRef
28.
Muller D, Thieke K, Burgin A, Dickmanns A, Eilers M: Cyclin E mediated elimination of p27 requires its interaction with the nuclear pore associated protein mNPAP60. EMBO J. 2000, 19: 2168-2180.PubMedPubMedCentralCrossRef
29.
Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, Nabel EG: A growth factor-dependent nuclear kinase phosphorylates p27Kip1 and regulates cell cycle progression. EMBO J. 2002, 21: 3390-3401.PubMedPubMedCentralCrossRef
30.
Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, Meloche S: p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 2001, 20: 6672-6682.PubMedPubMedCentralCrossRef
31.
Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 1997, 11: 1464-1478.PubMedCrossRef
32.
33.
Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M: Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999, 13: 1181-1189.PubMedPubMedCentralCrossRef
34.
Ohta T, Michel JJ, Schottelius AJ, Xiong Y: ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell. 1999, 3: 535-541.PubMedCrossRef
35.
Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999, 1: 193-199.PubMedCrossRef
36.
Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H: p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27. Curr Biol. 1999, 9: 661-664.PubMedCrossRef
37.
Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W: p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol. 1999, 1: 207-214.PubMedCrossRef
38.
Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, Reed SI: A CDK-independent function of mammalian Cks1: targeting of SCFSkp2 to the CDK inhibitor p27Kip1. Mol Cell. 2001, 7: 639-650.PubMedCrossRef
39.
Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M, Hershko A: The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27. Nat Cell Biol. 2001, 3: 321-324.PubMedCrossRef
40.
Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S, Nakayama KI: Degradation of p27Kip1 at the G0–G1 transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem. 2001, 276: 48937-48943.PubMedCrossRef
41.
Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene p27 Kip1 is haplo-insufficient for tumour suppression. Nature. 1998, 396: 177-180.PubMedCrossRef
42.
Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Young YL, Bartram CR, Koeffler HP: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27 Kip1 in human malignancies. Cancer Res. 1995, 55: 2266-2269.PubMed
43.
Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD, Vogelstein B: Assignment of human p27 Kip1 gene to 12p13 and its analysis in luekemias. Cancer Res. 1995, 55: 1206-1210.PubMed
44.
Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massagué J, Cordon-Cardo C: p27 Kip1 : chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumours. Cancer Res. 1995, 55: 1211-1214.PubMed
45.
Viglietto G, Fusco A: Understanding p27kip1 deregulation in cancer: down-regulation or mislocalization?. Cell Cycle. 2002, 1: 394-400.PubMedCrossRef
46.
Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X: High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA. 1997, 94: 6380-6385.PubMedPubMedCentralCrossRef
47.
Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 1997, 57: 1259-1263.PubMed
48.
Guo Y, Sklar GN, Borkowski A, Kyprianou N: Loss of the cyclin-dependent kinase inhibitor p27Kip1 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res. 1997, 3: 2269-2274.PubMed
49.
Piva R, Cavalla P, Bortolotto S, Cordera S, Richiardi P, Schiffer D: p27/kip1 expression in human astrocytic gliomas. Neurosci Lett. 1997, 234: 127-130.PubMedCrossRef
50.
Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H, Weinstein IB: Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res. 1998, 58: 114-122.PubMed
51.
Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G: Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst. 1998, 90: 916-920.PubMedCrossRef
52.
Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 1998, 58: 1730-1735.PubMed
53.
Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbiera-nowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM: Loss of cyclin dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998, 58: 542-548.PubMed
54.
Yang RM, Naitoh J, Murphy M, Wang HJ, Philipson J, deKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998, 159: 941-945.PubMedCrossRef
55.
Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd F, Slingerland JM: Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a potential prognostic factor independent of ras. Cancer Res. 1999, 59: 684-688.PubMed
56.
Piva R, Cancelli I, Cavalla P, Bortolotto S, Dominguez J, Draetta GF, Schiffer D: Proteasome-dependent degradation of p27/ kip1 in gliomas. J Neuropathol Exp Neurol. 1999, 58: 691-696.PubMedCrossRef
57.
Mizumatsu S, Tamiya T, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T: Expression of cell cycle regulator p27 Kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res. 1999, 5: 551-557.PubMed
58.
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997, 3: 231-234.PubMedCrossRef
59.
Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997, 57: 3381-3385.PubMed
60.
Chiarle R, Budel L, Skolnik J, Frizzera G, Chilosi M, Corato A, Pizzolo G, Magidson J, Montagnoli A, Pagano M, Maes B, DeWolf C, Inghirani G: Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood.
61.
Hershko D, Bornstein G, Ben Izhak O, Carrano A, Pagano M, Krausz MM, Hershko A: Inverse relation between levels of p27Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer. 2001, 91: 1745-1751.PubMedCrossRef
62.
Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T: High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 2001, 61: 7044-7047.PubMed
63.
Latres E, Chiarle R, Schulman BA, Pavletich NP, Pellicer A, Inghirami G, Pagano M: Role of the F-box protein Skp2 in lym-phomagenesis. Proc Natl Acad Sci USA. 2001, 98: 2515-2520.PubMedPubMedCentralCrossRef
64.
Yokoi S, Yasui K, Saito-Ohara F, Koshikawa K, Iizasa T, Fujisawa T, Terasaki T, Horii A, Takahashi T, Hirohashi S, Inazawa J: A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol. 2002, 161: 207-216.PubMedPubMedCentralCrossRef
65.
Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, Nakayama K, Mori M: Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002, 62: 3819-3825.PubMed
66.
Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W: Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA. 2001, 98: 5043-5048.PubMedPubMedCentralCrossRef
67.
Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L, Garcia JF, Piris MA: Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood. 1999, 94: 765-772.PubMed
68.
Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B: Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 1996, 15: 6595-6604.PubMedPubMedCentral
69.
Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, Eilers M: Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999, 18: 5321-5333.PubMedPubMedCentralCrossRef
70.
Perez-Roger I, Kim SH, Griffiths B, Sweing A, Land H: Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21Cip1. EMBO J. 1999, 18: 5310-5320.PubMedPubMedCentralCrossRef
71.
Gartel AL, Shchors K: Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res. 2003, 283: 17-21.PubMedCrossRef
72.
Weber JD, Hu W, Jefcoat SC, Raben DM, Baldassare JJ: Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem. 1997, 272: 32966-32971.PubMedCrossRef
73.
Balmanno K, Cook SJ: Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene. 1999, 18: 3085-3097.PubMedCrossRef
74.
Sears RC, Nevins JR: Signaling networks that link cell proliferation and cell fate. J Biol Chem. 2002, 277: 11617-11620.PubMedCrossRef
75.
Alt JR, Cleveland JL, Hannink M, Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2001, 14: 3102-3114.CrossRef
76.
Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12: 3499-3511.PubMedPubMedCentralCrossRef
77.
Fiorentino M, Altimari A, D'Errico A, Cukor B, Barozzi C, Loda M, Grigioni WF: Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res. 2000, 10: 3966-3972.
78.
79.
Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F, Barone MV, Chiappetta G, Vento MT, Spiezia S, Fusco A, Viglietto G: Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest. 1999, 104: 865-874.PubMedPubMedCentralCrossRef
80.
Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadini A, Mancuso S, Scambia G, Giordano A: Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res. 1999, 59: 3790-3794.PubMed
81.
Li JQ, Miki H, Wu F, Saoo K, Nishioka M, Ohmori M, Imaida K: Cyclin A correlates with carcinogenesis and metastasis, and p27kip1 correlates with lymphatic invasion, in colorectal neoplasms. Hum Pathol. 2002, 33: 1006-1015.PubMedCrossRef
82.
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL: PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med. 2002, 8: 1145-1152.PubMedCrossRef
83.
Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002, 8: 1136-1144.PubMedCrossRef
84.
Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002, 8: 1153-1160.PubMedCrossRef
85.
86.
McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF: Novel p27kip1 C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol. 2003, 23: 216-228.PubMedPubMedCentralCrossRef
87.
Aktas H, Cai H, Cooper GM: Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol. 1997, 17: 3850-3857.PubMedPubMedCentralCrossRef
88.
Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S, Uehara Y: Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene. 1997, 15: 629-637.PubMedCrossRef
89.
Takuwa N, Takuwa Y: Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol. 1997, 17: 5348-5358.PubMedPubMedCentralCrossRef
90.
Hoshino R, Tanimura S, Watanabe K, Kataoka T, Kohno M: Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27Kip1. J Biol Chem. 2001, 276: 2686-2692.PubMedCrossRef
91.
Alessandrini A, Chiaur DS, Erikson R, Pagano M: Regulation of the cyclin-depedent kinase inhibitor p27 by degradation and phosphorylation. Leukemia. 1997, 11: 342-345.PubMedCrossRef
92.
Liu X, Sun Y, Ehrlich M, Lu T, Kloog Y, Weinberg RA, Lodish HF, Henis YI: Disruption of TGF-β growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene. 2000, 19: 5926-5935.PubMedCrossRef
93.
Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, Oeda T, Tahara K, Terano T, Narumiya S, Kohn LD, Saito Y: Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem. 1997, 272: 13-16.PubMedCrossRef
94.
Hu W, Bellone CJ, Baldassare JJ: RhoA stimulates p27Kip degradation through its regulation of cyclin E/CDK2 activity. J Biol Chem. 1999, 274: 3396-3401.PubMedCrossRef
95.
Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL: ErbB2/neu kinase modulates cellular p27Kip1 and cyclin D1 through multiple signaling pathways. Cancer Res. 2001, 61: 6583-6591.PubMed
96.
Yang HY, Zhou BP, Hung MC, Lee MH: Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J Biol Chem. 2000, 275: 24735-24739.PubMedCrossRef
97.
Donovan JC, Milic A, Slingerland JM: Constitutive MEK/MAPK activation leads to p27Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem. 2001, 276: 40888-40895.PubMedCrossRef
98.
Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 1998, 52: 65-77.PubMedCrossRef
99.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the Her-2/Neu oncogene. Science. 1987, 235: 177-182.PubMedCrossRef
100.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712.PubMedCrossRef
101.
Newman L, Xia W, Yang HY, Sahin A, Bondy M, Lukmanji F, Hung MC, Lee MH: Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog. 2001, 30: 169-175.PubMedCrossRef
102.
Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortes-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A: Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer. 2003, 97: 1591-1600.PubMedCrossRef
103.
Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE: ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1–Cdk2 complex formation receptor overexpression does not determine growth dependency. Mol Cell Biol. 2000, 20: 3210-3223.PubMedPubMedCentralCrossRef
104.
Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 1994, 83: 2038-2044.PubMed
105.
Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993, 75: 175-185.PubMedCrossRef
106.
Skorski T, Kanakaraj P, Ku DH, Nieborowska-Skorska M, Canaani E, Zon G, Perussia B, Calabretta B: Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med. 1994, 179: 1855-1865.PubMedCrossRef
107.
Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M: Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res. 1996, 56: 3589-3596.PubMed
108.
Cortez D, Reuther G, Pendergast AM: The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 1997, 15: 2333-2342.PubMedCrossRef
109.
Weng LP, Brown JL, Eng C: PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet. 2001, 10: 599-604.PubMedCrossRef
110.
Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK: Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res. 2002, 62: 6764-6769.PubMed
111.
Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002, 62: 4132-4141.PubMed
112.
Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD: BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem. 2000, 275: 39223-39230.PubMedCrossRef
113.
Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ: Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology. 2001, 142: 4795-4805.PubMedCrossRef
114.
Forti FL, Schwindt TT, Moraes MS, Eichler CB, Armelin HA: ACTH promotion of p27Kip1 induction in mouse Y1 adrenocortical tumor cells is dependent on both PKA activation and Akt/PKB inactivation. Biochemistry. 2002, 41: 10133-10140.PubMedCrossRef
115.
Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H, Sun H: PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27KIP1 through the ubiquitin E3 ligase SCFSKP2. Curr Biol. 2001, 11: 263-267.PubMedCrossRef
116.
Wirbelauer C, Sutterluty H, Blondel M, Gstaiger M, Peter M, Reymond F, Krek W: The F-box protein Skp2 is a ubiquitylation target of a Cul1-based core ubiquitin ligase complex: evidence for a role of Cul1 in the suppression of Skp2 expression in quiescent fibroblasts. EMBO J. 2000, 19: 5362-5375.PubMedPubMedCentralCrossRef
117.
Yang G, Ayala G, Marzo AD, Tian W, Frolov A, Wheeler TM, Thompson TC, Harper JW: Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002, 8: 3419-3426.PubMed
118.
McManus EJ, Alessi DR: TSC1–TSC2: a complex tale of PKB-mediated S6K regulation. Nat Cell Biol. 2002, 4: E214-E216.PubMedCrossRef
119.
120.
Soucek T, Yeung RS, Hengstschlager M: Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA. 1998, 95: 15653-15658.PubMedPubMedCentralCrossRef
121.
Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massagué J, Crabtree GR, Roberts JM: Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994, 372: 570-573.PubMedCrossRef
122.
Firpo EJ, Koff A, Solomon MJ, Roberts JM: Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol. 1994, 14: 4889-4901.PubMedPubMedCentralCrossRef
123.
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997, 3: 227-230.PubMedCrossRef
124.
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997, 3: 222-225.PubMedCrossRef
125.
Loden M, Nielsen NH, Roos G, Emdin SO, Landberg G: Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene. 1999, 18: 2557-2566.PubMedCrossRef
126.
De Paola F, Vecci AM, Granato AM, Liverani M, Monti F, Innoceta AM, Gianni L, Saragoni L, Ricci M, Falcini F, Amadori D, Volpi A: p27/kip1 expression in normal epithelium, benign and neoplastic breast lesions. J Pathol. 2002, 196: 26-31.PubMedCrossRef
127.
Moriya T, Sakamoto K, Sasano H, Kawanaka M, Sonoo H, Manabe T, Ito J: Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod Pathol. 2000, 13: 13-18.PubMedCrossRef
128.
Reed W, Florems VA, Holm R, Hannisdal E, Nesland JM: Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch. 1999, 435: 116-124.PubMedCrossRef
129.
Soslow RA, Carlson DL, Horenstein MG, Osborne MP: A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas. Breast Cancer Res Treat. 2000, 61: 161-170.PubMedCrossRef
130.
Gillett CE, Smith P, Peters G, Lu X, Barnes DM: Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J Pathol. 1999, 187: 200-206.PubMedCrossRef
131.
Tsuchiya A, Zhang GJ, Kanno M: Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J Surg Oncol. 1999, 70: 230-234.PubMedCrossRef
132.
Wu J, Shen A-A, Lu JS, Jiang M, Han Q-X, Fontana JA, Barsky SH, Shao Z-M: Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br J Cancer. 1999, 79: 1572-1578.PubMedPubMedCentralCrossRef
133.
Barbareschi M, van Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla PP, Michalides R: p27kip1 expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer. 2000, 89: 236-241.PubMedCrossRef
134.
Leong ACK, Hanby AM, Potts HWW, Tan DSP, Skilton D, Ryder K, Harris WH, Liebmann RD, Barnes DM, Gillett CE: Cell cycle proteins do not predict the outcome in grade I infiltrating ductal carcinoma of the breast. Int J Cancer. 2000, 89: 26-31.PubMedCrossRef
135.
Chappuis PO, Kapusta L, Begin LR, Wong N, Brunet JS, Narod SA, Slingerland J, Foulkes WD: Germline BRCA1/2 mutations and p27Kip1 protein levels independently predict outcome after breast cancer. J Clin Oncol. 2000, 18: 4045-4052.PubMed
136.
Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C: p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat. 2001, 67: 15-22.PubMedCrossRef
137.
Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R, Morelli L, Leonardi E, Bevilacqua G, Dalla Palma P, Harris AL: p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer. 1996, 74: 208-215.PubMedPubMedCentralCrossRef
138.
Polyak C, Lee MH, Erdjument-romage H, Koff A, Roberts J, Tempst P, Massagué J: Cloning of p27KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994, 78: 59-66.PubMedCrossRef
Metadata
Title
Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer
Authors
Angel Alkarain
Joyce Slingerland
Publication date
01-02-2003
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2003
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr722

Other articles of this Issue 1/2003

Breast Cancer Research 1/2003 Go to the issue

Research article

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

Article selection

Articles selected from Faculty of 1000 in November 2003

Research article

Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer

Review

Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy

Research article

Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments

Letter

The diagnosis and management of pre-invasive breast disease: editor's reply
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits